Treatment of osteoporosis: Bisphosphonates as an alternative to hormone replacement therapy

Current Obstetrics and Gynaecology

Volumn 6, Issue 4, 1996, Pages 206-211

  Parker, C ^a   Hosking, D ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID;

BONE DENSITY; BONE MINERAL; BONE REMODELING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; HORMONE SUBSTITUTION; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; SHORT SURVEY;

EID: 0030498545     PISSN: 09575847     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0957-5847(96)80068-0     Document Type: Article

References (11)

1. Who Study Group. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. World Health Organization Technical Report Series 843
2. Lindsay R, Aitken JM, Anderson JB, Hart DM, MacDonald EB, Clark AC. Long term prevention of post-menopausal osteoporosis by oestrogens. Lancet 1976; (i):1038-1041
3. Sato M, Grasser W, Endo N, Akins R et al. Bisphosphonate action. Alendronate localisation in rat bone and effects on osteoclast structure. Clin Invest 1991;88:2095-2105
4. Fleisch H. New bisphosphonates in osteoporosis. Osteoporosis Int 1993; Suppl 2:515-522
5. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BE A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 1996; 11: 150-159
6. Chestnut CH, McClung MR, Ensrud KE et al. Alendronate treatment of the post-menopausal woman: effect of multiple dosages on bone mass and bone remodelling. Am J Med 1995; 99:144-152
7. Mosekilde L, Weisbrode SE, Safron JA et al. Calcium restricted ovariectomized Sinclair S-1 minipigs: An animal model for osteopenia and trabecular plate perforation. Bone 1993; 14: 379-382
8. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with post-menopausal osteoporosis. N Engl J Med 1990; 322: 1265-1271
9. Watts NB, Harris ST, Genant HK, Wasnich RD et al. Intermittent cyclical etidronate treatment of post-menopausal osteoporosis. N Engl J Med 1990; 323: 73-79
10. Harris ST, Watts NB, Jackson RD, Genant HK et al. Four year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95: 557-567
11. Valkema R, Vismans F-J FE, Papapoulos SE, Pauwels EKJ, Bijvoet OLM. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone and Mineral 1989; 5: 183-192